Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.

The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.

The government payor made some adjustments in finalizing the 2018 clinical lab fee schedule, but the industry continues to feel CMS is ignoring its most salient concerns.

Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.

Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.

Next-generation sequencing (NGS) continues to revolutionize personalized medicine as NGS technology improves and costs continue to fall, resulting in an increased number of scientific and health-related applications. However, the success of a sequencing project rests on the sample quality and NGS library used to generate the data. Poor quality libraries will produce poor quality or biased sequencing data that can slow the advancement and clinical utility of this great new technology.